Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 691 to 705 of 753 results for adult social

  1. Dinutuximab beta for treating neuroblastoma (TA538)

    Evidence-based recommendations on dinutuximab beta (Qarziba) for high-risk neuroblastoma in people aged 12 months and over.

  2. Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

    Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

  3. Pegcetacoplan for treating geographic atrophy [ID4041]

    Discontinued Reference number: GID-TA11351

  4. iFuse for treating chronic sacroiliac joint pain (HTG488)

    Evidence-based recommendations on iFuse for treating chronic sacroiliac joint pain.

  5. Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

    In development Reference number: GID-TA10886 Expected publication date: TBC

  6. Digital platforms to support cardiac rehabilitation: early value assessment (HTG761)

    Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.

  7. Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

    Discontinued Reference number: GID-TA10416

  8. Specialist neonatal respiratory care for babies born preterm (NG124)

    This guideline covers specific aspects of respiratory support (for example, oxygen supplementation, assisted ventilation, treatment of some respiratory disorders, and aspects of monitoring) for preterm babies in hospital.

  9. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

    Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours.

  10. NICE real-world evidence framework (ECD9)

    This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  11. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)

    Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.

  12. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued Reference number: GID-TA10234

  13. Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)

    NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .

  14. Neonatal infection: antibiotics for prevention and treatment (NG195)

    This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women and pregnant trans men and non-binary people whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.

  15. Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)

    Evidence-based recommendations on gefitinib (Iressa) for untreated locally advanced or metastatic non-small-cell lung cancer in adults.